Ventricular tachycardia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:20:20 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Ventricular tachycardia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of AGP100 Safety and Effectiveness in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) https://clinicaltrials.eu/trial/study-of-agp100-safety-and-effectiveness-in-patients-with-catecholaminergic-polymorphic-ventricular-tachycardia-cpvt/ Wed, 27 May 2026 04:04:53 +0000 https://clinicaltrials.eu/trial/study-of-agp100-safety-and-effectiveness-in-patients-with-catecholaminergic-polymorphic-ventricular-tachycardia-cpvt/ This study focuses on patients with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), a rare heart rhythm disorder that can cause dangerous irregular heartbeats during physical activity or emotional stress. The research evaluates a new medication called DNS-6288 (also known as AGP100) in capsule form, which will be taken orally in addition to standard heart medications.

The main purpose of this research is to determine if DNS-6288 is safe and well-tolerated by patients who have genetically confirmed CPVT and still experience irregular heartbeats during exercise, despite taking their regular medications. The study will test different doses of DNS-6288, with participants receiving up to 50 milligrams per day over a treatment period of 39 weeks.

During the study, participants will undergo regular check-ups that include exercise testing on a bicycle to monitor their heart rhythm. The research team will collect information about any side effects and measure how well the medication works by tracking changes in heart rhythm patterns during exercise. Blood and urine samples will also be collected to understand how the medication works in the body.

]]> Study on the Safety and Effects of CRD-4730 for Patients with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-crd-4730-for-patients-with-catecholaminergic-polymorphic-ventricular-tachycardia-cpvt/ Wed, 29 Apr 2026 15:04:17 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-crd-4730-for-patients-with-catecholaminergic-polymorphic-ventricular-tachycardia-cpvt/ This clinical trial is focused on studying a condition known as Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). CPVT is a rare heart rhythm disorder that can cause irregular heartbeats, especially during physical activity or stress. The study will evaluate a new treatment called CRD-4730, which is a tablet designed to help manage this condition. CRD-4730 works as a small molecule inhibitor, targeting specific proteins involved in heart rhythm regulation.

The purpose of the study is to assess the safety and tolerability of CRD-4730 in individuals with CPVT. Participants will receive either the CRD-4730 tablet or a matching placebo. The study is designed as a crossover trial, meaning participants will receive both the treatment and the placebo at different times. This approach helps researchers compare the effects of the actual medication against the placebo. The study will involve repeated doses of the medication over a period of time, allowing researchers to monitor how the body processes the drug and its impact on heart rhythm.

Throughout the study, participants will be closely monitored for any side effects or changes in their condition. The trial aims to provide valuable information on how CRD-4730 can be used to improve the management of CPVT, potentially offering a new treatment option for those affected by this challenging condition.

]]> Study on the Safety of CRD-4730 for Patients with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) https://clinicaltrials.eu/trial/study-on-the-safety-of-crd-4730-for-patients-with-catecholaminergic-polymorphic-ventricular-tachycardia-cpvt/ Wed, 29 Apr 2026 14:47:48 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-crd-4730-for-patients-with-catecholaminergic-polymorphic-ventricular-tachycardia-cpvt-2/ This clinical trial is focused on studying a heart condition called Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). CPVT is a rare genetic disorder that can cause irregular heartbeats, especially during physical activity or stress. The study will test a new treatment called CRD-4730, which is taken as a capsule. The purpose of the study is to evaluate the safety and tolerability of CRD-4730 in people with CPVT.

Participants in the study will receive either the CRD-4730 capsule or a placebo. The study is designed to be “blinded,” meaning that neither the participants nor the investigators will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are unbiased. The study will monitor participants over a period of time to observe any side effects and to measure how the body processes the medication.

Throughout the study, participants will undergo various tests, including blood tests and heart monitoring, to assess their health and the effects of the medication. The study aims to gather information on how CRD-4730 affects heart rhythm and its overall safety in treating CPVT. This research could potentially lead to new treatment options for individuals living with this challenging heart condition.

]]> Comparison of Carvedilol and Flecainide Treatment in Patients with Idiopathic Ventricular Arrhythmias https://clinicaltrials.eu/trial/study-comparing-carvedilol-and-flecainide-for-patients-with-idiopathic-ventricular-arrhythmias/ Wed, 29 Apr 2026 14:30:34 +0000 https://clinicaltrials.eu/trial/study-comparing-carvedilol-and-flecainide-for-patients-with-idiopathic-ventricular-arrhythmias/ This clinical trial focuses on idiopathic ventricular arrhythmias, a heart condition where the heart beats irregularly without a known cause. The study compares two medications: carvedilol and flecainide, which are taken as oral tablets to treat irregular heart rhythms. The purpose is to determine which medication is more effective in reducing irregular heartbeats.

Participants will receive either carvedilol (up to 50 mg daily) or flecainide (up to 300 mg daily) for a period of 12 months. During the study, heart activity will be monitored using a Holter-ECG, which is a portable device that records heart rhythms over 24 hours. The recordings will be taken before starting treatment and after completing it.

The study will also look at how these medications affect overall quality of life and heart function. Heart function will be evaluated using echocardiography, a test that uses sound waves to create pictures of the heart. The study will track any side effects that participants may experience during the treatment period.

]]>